We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
Read MoreHide Full Article
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Two companies — Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) — dominate the weight-loss drug market and their stocks have surged in the recent past due to soaring demand for their products. There are a few other ways to play this market. Exchange-traded funds (ETFs) are the best ways to access this evolving market.
VanEck Pharmaceutical ETF (PPH - Free Report) , Obesity & Cardiometabolic ETF (HRTS - Free Report) , and Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report) are the ETFs to play this emerging market.
What Are GLP-1 Receptor Agonists?
GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%. GLP-1 (Glucagon-Like Peptide-1) receptor agonists, including semaglutide, are marketed under names like Ozempic and Wegovy.
Ozempic and Wegovy: Market Leaders
Novo Nordisk’s Ozempic and Wegovy are at the forefront of this market, particularly in addressing the obesity epidemic. Initially approved for Type 2 diabetes, Ozempic quickly gained off-label popularity for its significant weight loss effects. Wegovy, also developed by Novo Nordisk, is specifically designed for weight loss and received FDA approval for this purpose.
How Crowded Is the Weight Loss Drug Market?
Experts predict that GLP-1 drugs could become blockbuster products with multi-billion-dollar sales potential. Eli Lilly and Novo Nordisk, too, could face stiff competition. Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs, as quoted on CNBC.
CEO Adam Steensberg indicated early-stage trial results of its GLP-1 treatment in an interview with CNBC, but said that it is the company’s separate obesity drug candidate — Petrelintide, a long-acting amylin analog — that could set it apart in the weight-loss drug segment.
Note that Amylin mimics a different hunger-regulating hormone. As a result, Petrelintide could prove to be an alternative for users who are intolerant of GLP-1s. Plus, last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide.
San Diego-based Viking Therapeutics emerged as a competitor in the weight loss drug market in February after revealing promising data from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection. In March, the company disclosed plans to test an oral tablet version after a small stage trial indicated weight loss as high as 3.3%, as quoted on Forbes.
The Forbes article went on to point out that Terns Pharmaceuticalsis developing an oral weight loss drug targeting the GLP-1 hormone and expects to release 28-day data on weight loss from an early-stage trial in the second half of 2024.
San Francisco startup Structure Therapeutics is also developing an oral, once-daily GLP-1 drug named GSBR-1290. The drug topped Wall Street’s expectations in June when a mid-stage study revealed an average weight loss of around 6%, and the company announced plans to start another mid-stage trial toward the end of this year, per Forbes.
Biotech giant Amgen scrapped plans for an experimental weight loss pill in May but is still looking for a share of the market with MariTide, a monthly injection that is taken less frequently than popular weekly treatments from Lilly and Novo and notably appears to help some patients maintain weight loss, per a Forbes article.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win
In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications, particularly GLP-1 receptor agonists such as Ozempic and Wegovy. The global obesity rate has nearly tripled since 1975 and is expected to affect over half the population by 2035, per WHO and Goldman Sachs. The global market for anti-obesity medications is expected to reach $50 billion by 2030.
As the prevalence of obesity rises, so do related chronic conditions such as diabetes, heart disease and hypertension, creating a massive market for treatments like GLP-1 drugs. Pioneering GLP-1 treatments, such as Ozempic, Wegovy and Zepbound, are now at the forefront of medical advancements in weight management.
Two companies — Eli Lilly (LLY - Free Report) and Novo Nordisk (NVO - Free Report) — dominate the weight-loss drug market and their stocks have surged in the recent past due to soaring demand for their products. There are a few other ways to play this market. Exchange-traded funds (ETFs) are the best ways to access this evolving market.
VanEck Pharmaceutical ETF (PPH - Free Report) , Obesity & Cardiometabolic ETF (HRTS - Free Report) , and Amplify Weight Loss Drug & Treatment ETF (THNR - Free Report) are the ETFs to play this emerging market.
What Are GLP-1 Receptor Agonists?
GLP-1 medications, initially used to treat diabetes, were later discovered to suppress appetite and lead to considerable weight loss. Recent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms in humans and lower the risk of heart attack, stroke and cardiovascular death by approximately 20%. GLP-1 (Glucagon-Like Peptide-1) receptor agonists, including semaglutide, are marketed under names like Ozempic and Wegovy.
Ozempic and Wegovy: Market Leaders
Novo Nordisk’s Ozempic and Wegovy are at the forefront of this market, particularly in addressing the obesity epidemic. Initially approved for Type 2 diabetes, Ozempic quickly gained off-label popularity for its significant weight loss effects. Wegovy, also developed by Novo Nordisk, is specifically designed for weight loss and received FDA approval for this purpose.
How Crowded Is the Weight Loss Drug Market?
Experts predict that GLP-1 drugs could become blockbuster products with multi-billion-dollar sales potential. Eli Lilly and Novo Nordisk, too, could face stiff competition. Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs, as quoted on CNBC.
CEO Adam Steensberg indicated early-stage trial results of its GLP-1 treatment in an interview with CNBC, but said that it is the company’s separate obesity drug candidate — Petrelintide, a long-acting amylin analog — that could set it apart in the weight-loss drug segment.
Note that Amylin mimics a different hunger-regulating hormone. As a result, Petrelintide could prove to be an alternative for users who are intolerant of GLP-1s. Plus, last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide.
San Diego-based Viking Therapeutics emerged as a competitor in the weight loss drug market in February after revealing promising data from a mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when given as a weekly injection. In March, the company disclosed plans to test an oral tablet version after a small stage trial indicated weight loss as high as 3.3%, as quoted on Forbes.
The Forbes article went on to point out that Terns Pharmaceuticals is developing an oral weight loss drug targeting the GLP-1 hormone and expects to release 28-day data on weight loss from an early-stage trial in the second half of 2024.
San Francisco startup Structure Therapeutics is also developing an oral, once-daily GLP-1 drug named GSBR-1290. The drug topped Wall Street’s expectations in June when a mid-stage study revealed an average weight loss of around 6%, and the company announced plans to start another mid-stage trial toward the end of this year, per Forbes.
Biotech giant Amgen scrapped plans for an experimental weight loss pill in May but is still looking for a share of the market with MariTide, a monthly injection that is taken less frequently than popular weekly treatments from Lilly and Novo and notably appears to help some patients maintain weight loss, per a Forbes article.